- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01314508
Increlex Treatment of Children With Chronic Liver Disease and Short Stature
A major consequence of chronic liver disease in childhood is growth failure. This is because a chemical essential for growth called growth factor is created in the liver. Lack of response to growth hormone in people with chronic liver disease is characterized by high levels of growth hormone and low levels of growth factors. This growth hormone resistance is reflected in a variety of factors including insulin resistance and low nutritional intake. Unfortunately, growth hormone therapy has no effect for children with liver disease. In addition, failure of normal growth or malnutrition makes liver disease even worse in children, and growth hormone therapy is not likely to reverse this. A lack of proper nutrition is associated with hospitalizations and frequent complications. Poor growth is a predictor of poor outcomes after liver transplantation. Thus the management of children with liver disease remains a challenge. Children who have successful orthotopic liver transplants (OLT) show much improvement in some aspects of growth, including skin fold thickness, mid-arm circumference, and normalization of growth factor levels. However, some studies have recently reported that the growth of 15-20% of children remains poor even after a liver transplant. This can be explained by persistent abnormalities in growth factors after transplant.
Growth factor was found to be a good tool for prognosis in patients with chronic liver disease. Studies showed that patients with liver cirrhosis and growth factor levels below normal values showed lower long-term survival rates compared with patients who had above normal values. This suggests that growth factor can be a good predictor of survival and early marker of poor liver function. In this case, aggressive feeding may modestly improve growth factor levels leading to improved growth but it is unlikely that effects will be optimal. The investigators propose that growth factor administration may have a positive effect that leads to better growth which is a major predictor of good outcome. To date, no reports study the use of growth factor in children with chronic liver disease. This study proposes to examine the effect of growth factor therapy in childhood chronic liver disease.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Fase
- Ikke aktuelt
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Pre liver transplant patients with:
- Chronic liver disease
- Short stature (< 5%)
- Low IGF-1 (<-1SDS for age)
- Chronologic age 4-18 and bone age < 14 for boys and < 12 for girls (pre-pubertal)
Exclusion Criteria:
- Status post transplant
- Evidence of malignancy
- Diabetes mellitus
- Participation in other clinical trials involving investigational products
- Treatment with growth hormone within 3 months
- Pregnancy
- Significant abnormality in clinical results
- Hypoglycemic at baseline
- Allergic to benzyl alcohol
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: All patients will be treated with IGF-1 factors
Patients will serve as their own control.
|
Increlex therapy will begin at 40 micrograms/kg/day twice a day.
The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Growth velocity is the primary outcome. Improved height SDS
Tidsramme: One year of therapy
|
Improved growth velocity with improved height standard deviation scores (SDS) is the primary expected result.
|
One year of therapy
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Improved BMI
Tidsramme: 12 months
|
An improved body mass index is a secondary expected result of this study.
|
12 months
|
Improved quality of life
Tidsramme: 12 months
|
An improved quality of life as assessed by the Pediatric Quality of Life Inventory forms is another expected result.
|
12 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 07-03-018
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Vekstsvikt
-
Yonsei UniversityFullførtFibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Reseptors (FGFRs) Genetisk avvik gastrisk kreft, INCB054828, PaclitaxelKorea, Republikken
-
Assistance Publique - Hôpitaux de ParisRekrutteringIntrauterin vekstbegrensning | Fetal Growth Restriction (FGR)Frankrike
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.FullførtAvansert brystkreft | HER2 forsterket | Human Epidermal Growth Factor Receptor 2 (HER2)Forente stater, Belgia, Canada, Italia, Spania, Storbritannia
-
Reshma L. Mahtani, D.O.Gilead SciencesRekrutteringBrystkreft | Avansert brystkreft | Metastatisk brystkreft | Hormonreseptor-positiv brystkreft | Human Epidermal Growth Factor 2 Lav brystkreftForente stater
-
University of British ColumbiaAvsluttetIntrauterin vekstrestriksjon (IUGR) | Fetal Growth Restriction (FGR)Canada
-
Carey Anders, M.D.Seagen Inc.RekrutteringAvansert brystkreft | Hjernemetastaser | Human Epidermal Growth Factor 2 Positivt brystkarsinomForente stater
-
Northwestern UniversityNational Cancer Institute (NCI); Boehringer Ingelheim; Robert H. Lurie Cancer...Aktiv, ikke rekrutterendeTilbakevendende akutt myeloid leukemi hos voksne | Refraktær Akutt Myeloid Leukemi | Akutt myeloid leukemi med t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Fibroblast Growth Factor Basic Form Measurement | FLT3 intern tandem dupliseringForente stater
Kliniske studier på Increlex
-
Nationwide Children's HospitalTercicaAvsluttet
-
Karolinska University HospitalFullført
-
University of Texas Southwestern Medical CenterAvsluttet
-
National Institute of Allergy and Infectious Diseases...AvsluttetVekstsvikt | X-bundet alvorlig kombinert immunsvikt (XSCID) | Resistens mot veksthormonForente stater
-
IpsenAvsluttetInsulinlignende vekstfaktor-1-mangelForente stater
-
Bispebjerg HospitalFullførtEhlers-Danlos syndrom, klassiskDanmark
-
IpsenUniversity of OklahomaFullført
-
Children's Hospital Medical Center, CincinnatiFullført
-
Peter BangFullførtType 1 diabetes mellitusSverige
-
Boston Children's HospitalAutism Speaks; International Rett Syndrome FoundationFullført